A backlog of referrals for suspected melanoma has grown hugely during the pandemic, adding to an already overwhelmed pathway. The vast majority of referred lesions turn out to be benign. Yet, there is an urgent need for a ‘rule-out’ test to focus resources through early reassurance of cases with no evidence of melanoma. Unlike the promise of automated diagnosis, ‘rule-out’ is technically an early deliverable.
Moletest (Scotland) Limited is the developer of nomela® – a rule-out test for melanoma. Our mission is to safely reduce referrals to Secondary Care as “no evidence of melanoma” by more than 50% generating substantial institutional savings and offering instantaneous patient reassurance.